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Although microbial populations in the gut microbiome are associated with
COVID-19 severity, a causal impact on patient health has not been established.
Here we provide evidence that gut microbiome dysbiosis is associated with
translocation of bacteria into the blood during COVID-19, causing lifethreatening secondary infections. We ﬁrst demonstrate SARS-CoV-2 infection
induces gut microbiome dysbiosis in mice, which correlated with alterations to
Paneth cells and goblet cells, and markers of barrier permeability. Samples
collected from 96 COVID-19 patients at two different clinical sites also revealed
substantial gut microbiome dysbiosis, including blooms of opportunistic
pathogenic bacterial genera known to include antimicrobial-resistant species.
Analysis of blood culture results testing for secondary microbial bloodstream
infections with paired microbiome data indicates that bacteria may translocate
from the gut into the systemic circulation of COVID-19 patients. These results
are consistent with a direct role for gut microbiome dysbiosis in enabling
dangerous secondary infections during COVID-19.

A better understanding of factors contributing to the pathology of
coronavirus disease 2019 (COVID-19) is an urgent global priority. Previous reports have demonstrated that severe COVID-19 is frequently
associated with speciﬁc inﬂammatory immune phenotypes, lymphopenia, and a generally disproportionate immune response leading to
systemic organ failure1,2. Even in mild cases, gastrointestinal symptoms
are reported frequently, and recent studies reported that COVID-19
patients lose commensal taxa of the gut microbiome during
hospitalization3–5, and persistent microbiome alterations are found in
patients with long-term complications from COVID-196–8. Differences
in gut bacterial populations relative to healthy controls were observed

in all COVID-19 patients, but most strongly in patients who were treated with antibiotics during their hospitalization4. Most recently,
COVID-19 patients treated with broad-spectrum antibiotics at admission were shown to have increased susceptibility to multi-drug resistant infections and nearly double the mortality rate from septic
shock9,10. Furthermore, although initially estimated to be low (6.5%)11,
more recent studies have detected bacterial secondary infections in as
much as 12–14% of COVID-19 patients12–14. However, the causal direction of the relationship between disease symptoms and gut bacterial
populations is not yet clear.
Complex gut microbiota ecosystems can prevent the invasion
of potentially pathogenic bacteria15,16. Conversely, when the gut
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microbiota incurs damage, such as through antibiotics treatment,
competitive exclusion of pathogens is weakened17–19 and potentially
dangerous blooms of antibiotic-resistant bacterial strains can
occur20,21. In immunocompromised cancer patients, blooms of Enterococcaceae and Gram-negative proteobacteria can lead to gut dominations by few or single species22–25. Such gut domination events are
dangerous to these patients because they are associated with
increased risk of translocation of antibiotic-resistant bacteria from the
gut into the blood stream22,26,27. Bacterial co-infection can also cause
life-threatening complications in patients with severe viral
infections10,11,28; therefore, antibacterial agents were administered
empirically to nearly all critically ill suspected COVID-19 patients since
the incidence of bacterial superinfection was unknown early during
the pandemic4,29. However, it is now known that nosocomial infection
during prolonged hospitalization is the primary threat to patients with
COVID-1930, rather than bacterial co-infection upon hospital
admission12,31–33. Evidence from immunocompromised cancer patients
suggests that indiscriminate administration of broad-spectrum antibiotics may, counter-intuitively, increase nosocomial bloodstream
infection (nBSI) rates by causing gut dominations of resistant microbes
that can translocate into the blood22,34. Indeed, we recently showed
that Enterococcus, a common gut microbial genus comprised of
intrinsically antibiotic-resistant strains, accounts for a large proportion
of nBSIs during longer hospitalizations, suggesting gut translocation35.
Thus, empiric antimicrobial use, i.e., without direct evidence for a
bacterial infection, in patients with severe COVID-19 may be especially
pernicious because it can select for antimicrobial resistance and promote gut translocation-associated nBSI.
The role of the gut microbiome in respiratory viral infections in
general36–39, and in COVID-19 patients, in particular, is only beginning
to be understood. Animal models of inﬂuenza virus infection have
uncovered mechanisms by which the microbiome inﬂuences antiviral
immunity40–42, and in turn, the viral infection was shown to disrupt the
intestinal barrier of mice by damaging the gut microbiota43,44. Here, we
show that infection by SARS-CoV-2 alone causes gut microbiome
dysbiosis and gut epithelial cell alterations in a mouse model. We
analyze stool samples obtained from two independent cohorts of
patients at NYU Langone Health and Yale New Haven Hospital, and ﬁnd
that COVID-19 is associated with severe microbiome injury characterized by loss of diversity and anaerobe taxa, resembling observations
made in the mouse model. Analysis of sequencing reads obtained from
stool samples together with results from blood cultures, we ﬁnd that
gut dysbiosis in COVID-19 patients is associated with secondary
bloodstream infections by gut bacteria.
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inconsistent (Supplementary Fig. 2a–d). Thus, we focused on ﬁndings from the 104 PFU inoculum.
Mice infected with 104 PFU displayed weight loss and other signs
of disease around day 4 (Supplementary Figs. 1a, b, 2h, i), alongside
microbiome changes characterized by a signiﬁcant loss of alpha
diversity (inverse Simpson index, Fig. 1b) corresponding to shifts in the
bacterial community composition (Fig. 1c, d). We performed time
series analyses on bacterial family abundances, contrasting their trajectories in infected (104 PFU) and uninfected mice. This revealed that
the strongest shift over time in infected mice was characterized by
signiﬁcant increases of Akkermansiaceae (p < 0.0002, Fig. 1d). Ranking
all bacterial family trajectories by their estimated changes over time in
infected mice showed that this increase in Akkermansiaceae was
accompanied by signiﬁcant losses of Clostridiaceae 1, a family of
obligate anaerobe bacteria, and of Erysipelotrichiaceae (Fig. 1e). We
also performed a trajectory analysis on the abundance of Proteobacteria, a phylum that comprises many pathogenic taxa that are a
major cause of nBSIs22; we observed a signiﬁcant increase of Proteobacteria over time in infected mice (Fig. 1e), but not in uninfected mice
(Supplementary Fig. 2e). This increase of Proteobacteria in infected
mice was driven by increase in several proteobacterial genera, with the
steepest increase observed in Escherichia/Shigella (Supplementary
Fig. 2f, g). These results demonstrated that SARS-CoV-2 infection leads
to gut microbiome dysbiosis over time in a mouse model.
We then determined if this dysbiosis was also associated with
intestinal defects that could enable translocation of bacteria into the
blood. In mice infected with 1000 PFU, bacterial translocation in
spleen and liver was observed in more of the infected mice compared
to uninfected controls (Supplementary Fig. 3a). However, while
several of the mice infected with 104 PFU displayed signs of barrier
dysfunction, the observed differences in plasma concentrations of
ﬂuorescein isothiocyanate (FITC)-dextran following its administration by gavage, or other markers of intestinal barrier permeability,
fatty acid-binding protein, lipopolysaccharide-binding protein, and
citrulline did not reach signiﬁcance (Supplementary Fig. 3b, c). The
reduced colon lengths, as well as reductions in the villus lengths in
the duodenum or ileum, i.e., markers of overt inﬂammation, that we
observed, were also non-signiﬁcant compared with control mice
(Supplementary Fig. 3d, e). Interestingly, infected mice that had
incurred the most severe microbiome injury in the form of diversity
loss also showed the most evidence of gut permeability—the highest
FITC-dextran concentrations in the blood of mice detected across all
samples came from the mice with the most extreme dysbiosis and
highest levels of Akkermansiaceae, a family of mucin-degrading
bacterial species (Supplementary Fig. 4).

Results
Gut microbiome dysbiosis in SARS-CoV-2-infected mice

SARS-CoV-2 infection alters gut epithelium in mice

We ﬁrst determined whether SARS-CoV-2 infection could directly
cause gut dysbiosis independently of hospitalization and treatment.
K18-hACE2 mice (K18-ACE2tg mice), express human ACE2 driven by
the cytokeratin-18 promoter (K18-ACE2tg mice). Although the overexpression of ACE2 prevents investigation of long-term consequences of infection due to potential non-speciﬁc disease, which
is a major limitation of the model, an advantage of these mice is that
they develop severe respiratory disease in a virus dose-dependent
manner, partially mirroring what is observed in COVID-19
patients45–48. Daily changes in fecal bacterial populations were
monitored following intranasal inoculation of mice with a range of
doses (10, 100, 1000, and 104 PFU) of SARS-CoV-2 or mocktreatment (Fig. 1a, Supplementary Fig. 1). Although we detected
viral RNA in the lungs but not in the intestine or stool as previously
observed49 of mice infected with doses as low as 100 PFU (Supplementary Fig. 1c), mice inoculated with doses lower than 104 PFU
displayed minimal or no signs of disease (Supplementary Fig. 1a, b).
As expected, based on this outcome, shifts in their microbiome were

Interestingly, we also detected a signiﬁcant increase in the number of
mucus-producing goblet cells and a decrease in the number of Paneth
cells in the ileum (but not in the duodenum) of infected mice (Fig. 2a, c
and Supplementary Fig. 3f). The decrease in Paneth cells was accompanied by structural abnormalities, most notably deformed or misplaced granules (Fig. 2b), and reduced gene expression of several
antimicrobial factors such as lysozyme, defensins, Reg3γ and serum
amyloid A in the ileum (Supplementary Fig. 3g). These morphological
abnormalities in Paneth cells were reminiscent of observations in the
ileum of patients with inﬂammatory bowel disease (IBD) as well as in a
virally-triggered animal model of IBD, where such structures were
indicative of defects in packaging and secretion of the granule protein
lysozyme50–52. Thus, to quantify the Paneth cell granule defect, we
performed lysozyme immunoﬂuorescence and found a signiﬁcant
increase in the proportion of Paneth cells displaying abnormal staining
patterns compared with the controls (Fig. 2b, c). We then investigated
if these physiological defects were associated with dysbiosis in the
microbiome.
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Fig. 1 | SARS-CoV-2 infection causes gut microbiome alterations in mice. K18hACE2 mice were infected intranasally with 0 or 104 PFU of SARS-CoV-2. Fecal
samples for microbiome analyses were collected daily from day 0 (before infection)
until sacriﬁce; mice were sacriﬁced on days 5–7. Results show pooled data from
three independent experiments with n = 3–5 mice per group. a Timelines of fecal
microbiota composition measured by 16S rRNA gene sequencing. Bars represent
the composition of the 15 most abundant bacterial families per sample for each day,
blocks of samples correspond to an individual mouse’s time course from day 0 to
day 6, as exempliﬁed for the ﬁrst mouse. b α-diversity (inverse Simpson index) per
infection group in the beginning (tstart, n = 13 each for control and infected) and at
the end (tend, n = 13 each for control and infected) of the experiment (n.s.: nonsigniﬁcant, **: p < 0.01, one-tailed, paired t-test; boxplots show median and quartile
ranges). Comparison between infected and non-infected mouse microbiomes at

the end of the experiment. c Principal coordinate plot of bacterial compositions in
samples collected prior to infection (tstart, top) and at sacriﬁce (tend, bottom) of the
experiment (Bray Curtis dissimilarity). d log10-relative family abundances at the
ﬁnal time point; boxplots show median and quartile ranges, whiskers extend to 1.5
times max- and min- quartile values, n.s.: not signiﬁcant; *: p value < 0.05; **: p
value < 0.01; ***: p value < 0.001; two-sided Wilcoxon rank-sum tests (n = 13 each for
control and infected). e Analysis of microbiome composition trajectories in infected mice. Regression coefﬁcients of the estimated changes in family abundances
per day in mice infected with 104 PFU were obtained from linear mixed effects
models with varying effects per mouse and per cage (only signiﬁcant coefﬁcient
results shown, abbreviations and colors as per the bacterial family legend; Red:
separate, analogous analysis for phylum Proteobacteria trajectories).

The most severely sick mice also had the most striking shifts in
their microbiome composition and the lowest microbiota diversity at
the end of the experiment (Supplementary Fig. 4a, b). To associate the
observed physiological defects with microbiome dysbiosis, we plotted
the numbers of goblet cells per crypt-villus unit and Paneth cells per
crypt, as well as the percentage of abnormal Paneth cells against bacterial alpha diversity and the log10-relative abundance of Akkermansiaceae (Fig. 2d, e). Goblet cell counts per crypt-villus unit were
negatively correlated with alpha diversity, and, conversely, positively
correlated with Akkermansiaceae. No statistically signiﬁcant association was found between diversity, Akkermansiaceae abundance, and
Paneth cell counts per crypt. However, we observed a striking signiﬁcant positive correlation between the percentage of abnormal
Paneth cells and Akkermansiaceae, and a corresponding negative
correlation with diversity. Altogether, these results show that the gut
microbiome dysbiosis observed in K18-hACE2 mice infected with a
high dose of SARS-CoV-2 is associated with alterations in key epithelial
cells, and signs of barrier permeability in the mice displaying the
greatest disruption in microbiome diversity.

as measured by the inverse Simpson index, in samples from both
centers (NYU: [1.0, 32.3], YALE: [1.5, 29.3], Fig. 3b); on average, samples
from NYU were less diverse (−4, p < 0.01, two-tailedT test, Fig. 3c), and
as reported previously, samples from patients admitted to the ICU had
reduced diversity (−3.9, p < 0.05, two-tailedT test, Supplementary
Fig. 5a). However, the composition in samples between the two centers
did not show systematic compositional differences (Fig. 3d–f). On
average, in both centers, members of the phyla Firmicutes and Bacteroidetes represented the most abundant bacteria, followed by Proteobacteria (Fig. 3d). The wide range of bacterial diversities was
reﬂected in the high variability of bacterial compositions across samples (Fig. 3e, f). In samples from both centers, microbiome dominations, deﬁned as a community where a single genus reached more than
50% of the population, were observed frequently (NYU: 21 samples,
YALE: 12 samples), representing states of severe microbiome injury in
COVID-19 patients (Fig. 3g, Supplementary Fig. 5). Strikingly, samples
associated with a BSI, deﬁned here as a positive clinical blood culture
test result, had strongly reduced bacterial α-diversities (mean difference: −5.2, CIBEST[−8.2, −2.2], Fig. 3h).
The lower diversity associated with samples from 25 patients with
BSIs (26% of the patients, 15 NYU, 10 Yale, Supplementary Table 2) led
us to investigate their bacterial taxon compositions and the potential
that gut dysbiosis was associated with BSI events. Importantly, BSI
patients had received antibiotic treatments during hospitalization
(Supplementary Fig. 6, Supplementary Table 2), which could exacerbate COVID-19-induced shifts in microbiota populations20,21,24, and may
indeed be administered in response to a suspected or conﬁrmed BSI.
We noted that most BSI patients received antibiotics prior to their BSI,

Dysbiotic microbiomes and BSIs in COVID-19 patients
To investigate the microbiome in COVID-19 patients, we proﬁled the
bacterial composition of the fecal microbiome in 130 samples (Fig. 3a)
obtained from SARS-CoV-2 infected patients treated at NYU Langone
Health (NYU, 67 samples from 60 patients) and Yale New Haven Hospital (YALE, 63 samples from 36 patients, Supplementary Table 1).
Analysis of metagenomic data obtained from sequencing of the 16S
rRNA genes revealed a wide range of bacterial community diversities,
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with 6 out of 25 patients receiving antibiotics only after the detection
of BSI. Principal coordinate analysis of all stool samples indicated that
the BSI-associated samples spanned a broad range of compositions
(Fig. 3h). To identify bacterial abundance patterns that consistently
distinguished BSI from non-BSI-associated samples, we performed a
Bayesian logistic regression. The model estimated the association of
the ten most abundant bacterial genera with BSI cases, i.e., it identiﬁed
enrichment or depletion of bacterial genera in BSI associated samples
(Fig. 3i). This analysis revealed that the genus Faecalibacterium was
negatively associated with BSI (OR: −0.5, CI:[−0.86, −0.15]), which was
also observed when we included microbiome domination as an
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additional factor in the model (Supplementary Fig. 7a). However, our
analysis also included stool samples that were taken only after a
positive blood culture was obtained, calling into question the plausibility of gut translocation; a complementary analysis only using stool
samples obtained prior or on the same day of a positive blood culture
also identiﬁed Faecalibacterium as most negatively associated with BSI
(Supplementary Fig. 7b). Furthermore, a higher-resolution analysis
using amplicon sequencing variant (ASV) relative abundances as predictors of BSI (Supplementary Fig. 7c, d), identiﬁed an ASV of the
Faecalibacterium genus as most negatively associated with BSI, in
agreement with our main analysis. Faecalibacterium is an
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Fig. 2 | SARS-CoV-2 infection causes abnormalities in the gut epithelium of
mice. K18-hACE2 were inoculated intranasally with 104 PFU SARS-CoV-2 or mock
treatment. a Representative H&E-stained section of the ileum depicting crypt-villus
axes from mice at the end of the experiment. Green arrows indicate goblet cells,
scale bars correspond to 25 μm. Bottom panels show high magniﬁcation images of
the indicated crypt with black arrowheads pointing at Paneth cells, scale bars
correspond to 10 μm. b Representative anti-lysozyme immunoﬂuorescence images
of the ileal crypt (two images per group). White and orange dotted circles delineate
normal and abnormal Paneth cells, respectively. Abnormality is characterized by
distorted, depleted, or diffuse lysozyme distribution patterns in Paneth cells.
Lysozyme = red, DAPI = blue, scale bars correspond to 10 μm. c Quantiﬁcation of
goblet cell number per villus (left), Paneth cells per crypt (middle left) and ratio of
goblet cell number / Paneth cell number (middle right) based on H&E staining, and
frequency of normal versus abnormal Paneth cell lysozyme distribution pattern
based on the immunoﬂuorescence staining as depicted in b (right). Dots represent
the mean cell number per crypt-villus unit in each mouse, 50 units were counted

per mouse. Results were pooled from three independent experiments with n = 3–5
mice per group for each experiment (n = 8–14 control mice, 12–14 infected mice).
Some mice were excluded from the analysis when quality of the slides was too poor.
Boxplots indicate median and interquartile ranges (ns = non-signiﬁcant, p < 0.05; **,
p < 0.01; ***, p < 0.001; ****, p < 0.0001 two-sided Mann-Whitney U test).
d Correlation of Goblet cell number per villus (left, two-sided Pearson correlation
r = −0.48, p = 0.015), Paneth cells per crypt (middle, r = 0.14, p value = 0.483) and
frequency of abnormal Paneth cell lysozyme distribution pattern (right, r = −0.5528,
p = 0.014) for the mice shown in c with α-diversity (inverse Simpson) of the gut
microbiome measured at the last day before sacriﬁce. e Correlation of Goblet cell
number per villus (left, r = 0.63, p < 0.001), Paneth cells per crypt (middle, r = −0.29,
p = 0.149) and frequency of abnormal Paneth cell lysozyme distribution pattern
(right, r = 0.65, p value = 0.003) for the mice shown in c with log10-relative abundances of Akkermansia in fecal samples from the last day before sacriﬁce; lines:
univariate linear regression, shaded region: 95% CI.

Fig. 3 | The dysbiotic gut microbiome in COVID-19 in patients from NYU Langone Health (n = 60) and Yale New Haven Hospital (n = 36) is associated with
secondary bloodstream infections. a Bacterial family composition in stool samples (Yale, n = 63 samples; NYU, n = 67) identiﬁed by 16S rRNA gene sequencing;
bars represent the relative abundances of bacterial families; red circles indicate
samples with single taxa >50%. Samples are sorted by center and bacterial αdiversity (inverse Simpson index, b). c α-diversity in samples from NYU Langone
Health and Yale New Haven Hospital; p = 0.0065, two-sided T-test. d Average
phylum level composition per center. Principal coordinate plots of all samples
shown in a, labeled by center (e), most abundant bacterial family (f) and domination
status of the sample (g), and BSI status; inset: boxplot of inverse Simpson index

diversity by BSI (h). i Coefﬁcients from a Bayesian logistic regression with most
abundant bacterial genera as predictors of BSI status (circle: posterior mean, lines:
95% HDI). j Counterfactual posterior predictions of BSI risk based on bacterial
composition contrasting the predicted risk of the average composition across all
samples (red) with the risk predicted from a composition where Faecalibacterium
was increased by 10% (blue). k Shotgun metagenomic reads matched the species
identiﬁed in clinical blood cultures in 70% of all investigated cases; the histogram
shows the distribution of log10-ratios of relative abundances of matched species in
corresponding stool samples to their corresponding mean abundances across all
samples.

immunosupportive, short-chain fatty acid-producing genus that is a
prominent member of the human gut microbiome53–55, and its reduction is associated with disruption to intestinal barrier function56,57,
perhaps via ecological network effects57.
To evaluate the effect size of the association between Faecalibacterium and BSIs, we performed a counterfactual posterior predictive check. Using the average genus composition found across all
samples, we ﬁrst computed the distribution of predicted BSI risks
(Fig. 3j), and compared this risk distribution with a hypothetical

bacterial composition which increased Faecalibacterium by 10%
points. The predicted risk distributions associated with these two
compositions differed strongly (mean difference 15%, CI: [1%, 32%],
Fig. 3j). Domination states of the microbiome increase the risk for BSIs
in immunocompromised cancer patients22; such dominations imply
high relative abundances of single taxa, and therefore a low diversity.
Consistent with this, Faecalibacterium abundance was positively correlated with diversity (R: 0.55, p < 10−10, Supplementary Fig. 8) in our
data set and as reported previously53.
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We therefore next investigated a direct association between the
bacteria populating the gut microbiome and the organisms identiﬁed
in the blood of patients. Visualizing the bacterial composition in stool
samples from patients alongside the BSI microorganisms (Supplementary Fig. 9a) suggested a correspondence with the respective taxa
identiﬁed in the blood: high abundances of the BSI-causing microbes
were found in corresponding stool samples. A rank abundance analysis
matching the organisms identiﬁed in clinical blood cultures to the
composition of bacteria in corresponding stool samples indicated
enrichment of taxa belonging to the same bacterial orders as BSIcausing organisms (Supplementary Fig. 9b), suggesting translocation
of bacteria from the gut into the bloodstream.
To further investigate evidence for translocation of gut bacteria
into the blood, we next performed shotgun metagenomic sequencing
on a subset of BSI-associated samples with sufﬁcient remaining
material; this allowed us to match the organism identiﬁed in clinical
blood cultures at the species level with reads obtained from stool
samples (Fig. 3k, Supplementary Table 3). In four cases of positive
blood cultures of Staphylococcus species, no reads matching the
clinically identiﬁed species were detected (Supplementary Table 3).
This may explain why the rank analysis suggested that Staphylococcales were not generally enriched in BSIs by Staphylococcus (Supplementary Fig. 9a, b). Consistent with this, in one case of a S. aureus
BSI where corresponding stool relative abundances of Staphylococcus
were low, reads from shotgun sequencing did not match the genomes
of isolates obtained from the same patient better than S. aureus genomes from other isolates (Supplementary Fig. 9d). On the other hand,
several reference genomes of S. aureus have almost identical sequences, allowing reads from the stool sample to align almost the same
extent to all of them. Strikingly, shotgun metagenomic reads matched
the genome of isolates well in another case where relative abundances
of Staphylococcus were enriched in the stool (Supplementary Fig. 9c),
providing evidence that here, the same strains were found in stool and
blood of the same patient. In all investigated cases of positive blood
cultures by organisms other than Staphylococcus, the species identiﬁed in clinical blood cultures had corresponding reads in the stool
samples. Strikingly, the relative abundances of matched species tended to be larger than the average abundances of matched species
across all samples (Supplementary Table 3).

Discussion
Collectively, these results reveal an unappreciated link between SARSCoV-2 infection, gut microbiome dysbiosis, and a severe complication
of COVID-19, BSIs. The loss of diversity and immunosupportive Faecalibacterium in patients with BSIs mirrored a similar loss of diversity in
the most severely sick mice deliberately infected with SARS-CoV-2, and
as observed by other labs and other model systems58–60. Notably, a
recent study reproduced these changes in the microbiome in an
antibiotics-naïve cohort7, suggesting that the viral infection causes gut
dysbiosis, either through gastrointestinal infection61–65 or through a
systemic inﬂammatory response2,4. Furthermore, the pronounced
increase in Akkermansiaceae in mice was also observed in our patient
samples and has been reported previously in patients and in K18hACE2 mice58,66. However, the dysbiosis in patients with COVID-19
exceeded the microbiota shifts observed in the mouse experiments,
including microbiome dominations by single taxa, which was not seen
in the mouse experiments. It is possible that in our experiment, mice
were sacriﬁced before perturbations to the gut microbial populations
reached a maximum. hACE2 knock-in mice, which display reduced
disease45, were not tested in the scope of this study but could provide
additional insights in the future. However, it is also plausible that the
frequently administered antibiotic treatments that hospitalized
COVID-19 patients receive exacerbated SARS-CoV-2-induced microbiome perturbations. Additionally, unlike the controlled environment
experienced by laboratory mice, hospitalized patients are uniquely
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exposed to antimicrobial-resistant infectious agents present on surfaces and shed by other patients.
Despite these limitations of the mouse model, we observed that
SARS-CoV-2 infection led to alteration of intestinal epithelial cells with
established roles in intestinal homeostasis and gastrointestinal
disease67,68. Microbiome ecosystem shifts are likely both cause and
consequence of these epithelial cell alterations since epithelial secretions are predicted to affect overall community structure disproportionately strongly69,70. For example, disruption of Paneth cellderived antimicrobials including lysozyme are sufﬁcient to impact
microbiome composition71–73, and, conversely, Akkermansia, which
was increased in infected mice, can have epithelium remodeling
properties74. Akkermansia has emerged as a genus of major interest,
but its contributions to health or disease are still under research:
beneﬁcial health effects53,75, as well as detrimental associations, have
been reported76–78.
Our observation that the type of bacteria that entered the
bloodstream was enriched in the associated stool samples is a wellcharacterized phenomenon in cancer patients22,26,27, especially
during chemotherapy-induced leukocytopenia when patients are
severely immunocompromised20,53. COVID-19 patients are also
immunocompromised and frequently incur lymphopenia, rendering them susceptible to secondary infections79. Our data suggest
dynamics in COVID-19 patients may be similar to those observed in
cancer patients: BSI-causing organisms may translocate from the
gut into the blood, potentially due to loss of gut barrier integrity,
through tissue damage downstream of antiviral immunity instead of
chemotherapy. Consistent with this possibility, soluble immune
mediators such as TNFα and interferons produced during viral
infections, including SARS-CoV-2, damage the intestinal epithelium
to disrupt the gut barrier, especially when the inﬂammatory
response is sustained as observed in patients with severe COVID1952,80,81. Indeed, blood plasma in severely sick COVID-19 patients is
enriched for markers of disrupted barrier integrity and higher levels
of inﬂammation markers82, and nBSIs in these patients are often
caused by gut microbial taxa35, suggesting microbial translocation.
Our data support this model with direct evidence because we were
able to match sequencing reads from stool samples to genomes of
species detected in the blood of patients.
We presented evidence that microorganisms from the dysbiotic
gut microbiome translocate into the blood of COVID-19 patients,
plausibly due to a combination of the immunocompromising effects of
the viral infection and antibiotic-driven depletion of commensal gut
microbes. However, COVID-19 patients are also uniquely exposed to
other potential factors predisposing them to bacteremia, including
immunosuppressive drugs, long hospital stays, and catheters and our
study is limited in its ability to investigate their individual effects. Other
limitations of our data include the few available whole genome
sequences of blood isolates due to discarded blood cultures associated with several BSIs, and the temporal ordering of samples.
Occasionally stool samples were collected after observation of BSI, and
this mismatch in temporal ordering is counterintuitive for gut-toblood translocation and a causal interpretation of our associations.
However, the reverse direction, that blood infection populates and
changes the gut community, is unlikely for the organisms identiﬁed in
the blood, and if our associations were not causal, we would expect no
match between BSI organisms and stool compositions.
Taken together, our ﬁndings support a scenario in which gut-toblood translocation of microorganisms following microbiome dysbiosis leads to dangerous BSIs during COVID-19, a complication seen in
other immunocompromised patients, including patients with
cancer22,26,27,83, acute respiratory distress syndrome84, and in ICU
patients receiving probiotics85. We suggest that investigating the
underlying mechanism behind our observations will inform the judicious application of antibiotics and immunosuppressives in patients
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with respiratory viral infections and increase our resilience to
pandemics.

Methods
Statistics and reproducibility
No statistical method was used to predetermine sample size. The
experiments were not randomized; the investigators were not blinded
to allocation during experiments and outcome assessment.

Mouse experiments
Cells and virus. Vero E6 (CRL-1586; American Type Culture Collection)
were cultured in Dulbecco’s Modiﬁed Eagle’s Medium (Corning) supplemented with 10% fetal bovine serum (Atlanta Biologics) and 1%
nonessential amino acids (Corning). SARS-CoV-2, isolate USA-WA1/
2020 19 (BEI resources #NR52281), a gift from Dr. Mark Mulligan at the
NYU Langone Vaccine Center was ampliﬁed once in Vero E6 cells. All
experiments with SARS-CoV-2 were conducted in the NYU Grossman
School of Medicine ABSL3 facility in accordance with its Biosafety
Manual and Standard Operating Procedures, by personnel equipped
with powered air-purifying respirators.
Mice. Heterozygous K18-hACE2 C57BL/6J mice (strain: 2B6.Cg-Tg(K18ACE2)2Prlmn/J) were obtained from The Jackson Laboratory. Several
were paired with C57BL/6J mice to generate additional heterozygous
mice for subsequent experiments and the remaining were used to
perform initial experiments. Animals from the same breeder pool (i.e.,
littermates) were randomly assigned and housed in cages according to
the experimental groups in ventilated racks and provided autoclaved
water and standard chow ad libitum (dark/light cycle: 12/12 hours,
ambient temperature: 69–72 °F, humidity: 30–70%). Cage bedding was
mixed prior to infection in a subset of experiments to further reduce
possible cage effect. All animal studies were performed according to
protocols approved by the NYU School of Medicine Institutional Animal Care and Use Committee (IACUC n°170209 and 180802) and in the
ABSL3 facility of NYU Grossman School of Medicine (New York, NY), in
accordance with its Biosafety Manual and Standard Operating Procedures. 12-week-old or 24-week-old K18-hACE2 males were administered either 10-10000 PFU SARS-CoV-2 diluted in 50 µL PBS (Corning)
or 50 µL PBS (non-infected, 0) via intranasal administration under
xylazine-ketamine anesthesia (AnaSedR AKORN Animal Health, KetathesiaTM Henry Schein Inc). Viral titer in the inoculum was veriﬁed by
plaque assay in Vero E6 cells. Following infection, mice were monitored daily for weight loss, temperature loss and signs of disease. A
disease score was calculated as the sum of scores obtained for each of
the following criteria: rufﬂed fur (no = 0, yes = 1), hunched back (no =
0, slightly = 1, exacerbated = 2), heavy breathing (no = 0, yes = 1),
altered mobility (no = 1, reduced activity = 1, no mobility = 2). Stool
samples were collected and stored at −80 °C.
Quantitative real-time PCR to assess viral titer and antimicrobial
products. Whole lungs and 1 cm of proximal duodenum, terminal
ileum and proximal colon were collected 5 to 7 days after infection.
Intestinal pieces were wash with PBS and all organs were transferred in
Eppendorf tubes containing 500 μl of PBS and a 5 mm stainless steel
bead (Qiagen) and homogenized using the Qiagen TissueLyser II.
Homogenates were cleared for 5 min at 5000 × g, and the viral supernatant or nasal wash was diluted 4× in TRIzol reagent (Invitrogen) and
frozen at −80 °C for titration by qRT-PCR. RNA was extracted from the
TRIzol homogenates using chloroform separation and isopropanol
precipitation, followed by additional puriﬁcation using RNeasy spin
columns with DNase treatment according to the manufacturer’s
instructions (Rneasy Mini Kit; RNAse-Free DNase Set; QIAGEN). RNA
was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). To assess viral titer, qPCR was
performed using Applied Biosystems TaqMan RNA-to-CT One-Step Kit
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(Fisher-Scientiﬁc), 500 nM of the primers (Fwd 5′-ATGCTGCAATCGTGCTACAA-3′, Rev 5′-GACTGCCGCCTCTGCTC-3′) and
100 nM of the N probe (5′-/56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/−3′). qPCR reaction conditions were 48 °C for 15 min
followed by 95 °C for 2 min, and by 50 cycles of: 95 °C for 15 s, and
60 °C for 1 min. Serial dilutions of in vitro transcribed RNA of the SARSCoV-2 Nucleoprotein (generated as previously described86) were used
to generate a standard curve and calculate copy numbers per μg of
RNA in the samples.
To assess antimicrobial factors, qPCR was performed using
SybrGreen (Roche) on a Roche480II Lightcycler using 500 nM of the
primers listed in Supplementary Table 4. PCR reaction conditions were
95 °C for 5 min, followed by 45 cycles of: denaturation at 95 °C for 10 s,
annealing at 60 °C for 20 s, and extension at 72 °C for 30 s.
Microscopy. 5 cm of proximal duodenum, distal ileum, and entire
colon were ﬂushed with 10% acetate buffered formalin (Fisher scientiﬁc), cut open along the length, pinned on black wax and ﬁxed with
formalin for 72 h at RT. 2 cm strips of intestinal tissues were embedded
in low melting point agarose (Promega) to enrich for well-oriented
crypt-villus units. Parafﬁn embedding, sectioning, and staining were
performed by the NYU Experimental Pathology Research Laboratory.
5 μm sections were stained with hematoxylin and eosin and imaged
using brightﬁeld wholeslide scanning. Lysozyme staining was performed using anti-lysozyme (ab108508, Abcam) and DAPI immunostaining and analyzed using a Zeiss AxioObserver.Z1 with Axiocam 503
Mono operated with Zen Blue software. 50 small intestinal villi per
mouse were measured for villi length. Goblets cell were quantiﬁed
from 50 villus-crypt units (one villus + half of the 2 surrounding crypts)
per mouse. Paneth cells numbers and lysozyme staining patterns were
quantiﬁed from 50 crypts per mouse. Previously deﬁned criteria were
used to quantify the proportion of Paneth cells displaying abnormal
lysozyme staining52. Mean values were calculated for each mouse and
used as individual data points.
Measurement of intestinal permeability. Mice were fasted for 4 h
before oral gavage with 200 μL of FITC-dextran (3-5 kDa, SigmaAldrich) dissolved in sterile PBS (60 mg/ml). After 4 h, mice were
euthanized and blood was collected by cardiac puncture. FITC-dextran
in plasma was quantiﬁed using a plate reader (excitation, 485 nm;
emission, 530 nm). Citrulline, intestinal fatty acid-binding protein, and
lipopolysaccharide-binding protein were quantiﬁed in the plasma by
enzyme-linked immunosorbent assay according to the manufacturer’s
instructions (MyBioSource, CA). For bacterial translocation assay:
spleen and liver were homogenized using the Qiagen TissueLyser II
and plated on BBL™ Enterococcosel™ Agar, (BBL, modiﬁed esculin bile
agar, Becton Dickinson). This medium enriches for enterococci which
are often detected following a breach in barrier and will inhibit the
growth of most other microorganisms non-speciﬁcally present in these
organs. Plates were incubated at 37 °C. All colonies were enumerated.
Time series analyses of bacterial family abundances. We log10transformed bacterial relative abundances adding a pseudo count to
ﬁll zeros (2*10−6). We then analyzed the time series with the following
model that included ﬁxed effects for the intercepts and slopes of the
treatment (i.e., indicator variables for uninfected (0 PFU), and infected
(104 PFU), and random effects per cage and per mouse to account for
cage effects and repeated measurements from the same individuals,
respectively. The model was implemented in the R programming language using the lmerTest v3.1-3.
Time series analysis of proteobacterial genus abundances. We
altered the model for family abundances to account for sparser genus
level abundances by partial pooling data between genera. The genus
level model includes a varying intercept and varying slope for each
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genus, thereby estimating a trajectory for each genus. We only included genera that had non-zero relative abundances in at least ﬁve
samples; the other proteobacterial genera were under-powered.

in ref. 88 and a minimum boostrapping support of 50%. Species-level
taxonomy was assigned to ASVs only with 100% identity and unambiguous matching to the reference.

Human study

Shotgun metagenomic sequencing. DNA was quantiﬁed with QiantiT Picogreen dsDNA Assay (Invitrogen). Libraries were prepared with a
procedure adapted from the Nextera Library Prep kit (Illumina), and
sequenced on an Illumina NovaSeq using paired-end 2 × 150 reads
(Illumina) aiming for 100 M read depth. DNA sequences were ﬁltered
for low quality (Q-Score < 30) and length (<50), and adapter sequences
were trimmed using cutadapt. Fastq ﬁles were converted a single fasta
using shi7. Sequences were trimmed to a maximum length of 100 bp
prior to alignment. DNA sequences were taxonomically classiﬁed using
the MetaPhlAn2 v3 analysis tool (http://huttenhower.sph.harvard.edu/
metaphlan2). MetaPhlAn2 maps reads to clade-speciﬁc marker genes
identiﬁed from ~17,000 reference genomes and estimates clade
abundance within a sample from these mappings.

Study population and data collection. This study involved 96
patients with laboratory-conﬁrmed SARS-CoV-2 infection. SARS-CoV-2
infection was conﬁrmed by a positive result of real-time reverse
transcriptase-polymerase chain reaction assay on a nasopharyngeal
swab. 60 patients were seen at NYU Langone Health, New York,
between January 29, 2020–July 2, 2020. In order to be eligible for
inclusion in the study, stool specimens needed to be from individuals > 18 years of age. Data including demographic information,
clinical outcomes, and laboratory results were extracted from the
electronic medical records in the NYU Langone Health clinical management system. Blood and stool samples were collected by hospital
staff. OmnigeneGut kits were used on collected stool. In parallel, 36
patients were admitted to YNHH with COVID-19 between 18 March
2020 and 27 May 2020 as part of the YALE IMPACT cohort described at
length elsewhere2. Brieﬂy, participants were enrolled after providing
informed consent and paired blood and stool samples were collected
longitudinally where feasible for duration of hospital admission. No
statistical methods were used to predetermine sample size for this
cohort. Demographic information of patients was aggregated through
a systematic and retrospective review of the EHR and was used to
construct Supplementary Table 1. Symptom onset and etiology were
recorded through standardized interviews with patients or patient
surrogates upon enrollment in our study, or alternatively through
manual EHR review if no interview was possible owing to clinical status
at enrollment. The clinical data were collected using EPIC EHR and
REDCap 9.3.6 software. At the time of sample acquisition and processing, investigators were blinded to patient clinical status.
DNA extraction and bacterial 16S rRNA gene sequencing. For bacterial DNA extraction 700 µL of SL1 lysis buffer (NucleoSpin Soil kit,
Macherey-Nagel) was added to the stool samples and tubes were
heated at 95 °C for 2 h to inactivate SARS-CoV-2. Samples were then
homogenized using the FastPrep-24TM instrument (MP Biomedicals)
and extraction was pursued using the NucleoSpin Soil kit according to
the manufacturer’s instructions. DNA concentration was assessed
using a NanoDrop spectrophotometer. Samples with too low DNA
concentration were excluded. DNA from human samples was extracted with PowerSoil Pro (Qiagen) on the QiaCube HT (Qiagen), using
Powerbead Pro (Qiagen) plates with 0.5 mm and 0.1 mm ceramic
beads. For mouse samples, the variable region 4 (V4) of the 16S rRNA
gene was ampliﬁed by PCR using primers containing adapters for
MiSeq sequencing and single-index barcodes. All PCR products were
analyzed with the Agilent TapeStation for quality control and then
pooled equimolar and sequenced directly in the Illumina MiSeq platform using the 2 × 250 bp protocol. Human samples were prepared
with a protocol derived from87, using KAPA HiFi Polymerase to amplify
the V4 region of the 16 S rRNA gene. Libraries were sequenced on an
Illumina MiSeq using paired-end 2 × 250 reads and the MiSeq
Reagent Kitv2.
Bioinformatic processing and taxonomic assignment. Amplicon
sequence variants (ASVs) were generated via dada2 v1.16.0 using postQC FASTQ ﬁles. Within the workﬂow, the paired FASTQ reads were
trimmed, and then ﬁltered to remove reads containing Ns, or with
maximum expected errors ≥ 2. The dada2 learn error rate model was
used to estimate the error proﬁle prior to using the core dada2 algorithm for inferring the sample composition. Forward and reverse reads
were merged by overlapping sequence, and chimeras were removed
before taxonomic assignment. ASV taxonomy was assigned up to
genus level using the SILVAv.138 database with the method described
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Mapping shotgun reads to whole genome sequences of clinical
isolates. Quality-controlled reads were re-classiﬁed using Kraken2
(Minikraken2 v2 database, available on https://ccb.jhu.edu/software/
kraken2/index.shtml). Reads that were classiﬁed by Kraken2 as Staphylococcus aureus (or a strain thereof) were further mapped using
Bowtie2 separately to each of a collection of Staphylococcus aureus
isolates. The collection was composed of all NCBI RefSeq assemblies as
of 11/17/2021, in addition to Staphylococcus aureus isolates that were
isolated from our subjects. Bowtie2 mapped reads were then further
ﬁltered, keeping only reads that mapped without mismatches. A
neighbor-joining tree was produced from this collection of genomes
using Snippy (https://github.com/tseemann/snippy).

Compositional analyses
α-Diversity. We calculated the inverse Simpson index from relative
ASV abundances (p) with N ASVs in a given sample, Eq. (1):
1
IV S = PN
i

p2i

ð1Þ

Principal coordinate analyses. Bray–Curtis distances were calculated
from the ﬁltered ASV table using QIIME v1.9.1 and principal components of the resulting distance matrix were calculated using the scikitlearn v1.0.2 package for the Python programming language, used to
embed sample compositions in the ﬁrst two principal coordinates.
Average compositions and manipulation of compositions. To
describe the average composition of a set of samples we calculated the
central tendency of a compositional sample89. For counter factual
statistical analyses that require changes to a composition, e.g., an
increase in a speciﬁc taxon, we deployed the perturbation operation
(⊕), which is the compositional analog to addition in Euclidean
space89. A sample x containing the original relative taxon abundances
is perturbed by a vector y, Eq. (2):
"
#
x y
x y
x y
y : x # y = PD 1 1 , PD2 2 ,. . ., PDD D 8x, y 2 SD
i = 1 x i yi
i = 1 x i yi
i = 1 x i yi

ð2Þ

where SD represents the D-part simplex.
Bayesian t-test. To compare diversity measurements between different sample groups, e.g., different clinical status, we performed a
Bayesian estimation of group differences (BEST90), implemented using
the pymc3 v3.11 package for the Python programming language; with
priors (∼) and deterministic calculations (=) to assess differences in
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estimated group means as follows:
g1 ~ Normalðμ = 15, σ = 15Þ
g2 ~ Normalðμ = 15, σ = 15Þ

σ g1 ~ Uniformðlow = 1e & 4, high = 30Þ
σ g2 ~ Uniformðlow = 1e & 4, high = 30Þ
ν ~ Exponentialð1=15Þ + 1
λ1 = σ g1 &2
λ2 = σ g2 &2

some cases, the binary indicator variable for gut microbiome
domination.

Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The raw sequencing data have been deposited on the Sequencing
Reads Archive (SRA), and SRA accession numbers are available for two
bioprojects corresponding to the mouse sequencing data
PRJNA745367 (Supplementary Data 1, https://www.ncbi.nlm.nih.gov/
bioproject/PRJNA745367) and the human stool samples PRJNA746322
(Supplementary Data 2, https://www.ncbi.nlm.nih.gov/bioproject/
PRJNA746322). Databases/sets used in this study include SILVAv.138
(https://www.arb-silva.de/documentation/release-138/), Minikraken2
v2 (https://ccb.jhu.edu/software/kraken2/index.shtml), and all of the
NCBI RefSeq assemblies as of 11/17/2021.

Code availability
G1 ~ StudentTðnu = ν, mu = g1, lam = λ1 Þ
G2 ~ StudentTðnu = ν, mu = g2, lam = λ2 Þ

The relevant analyses were implemented in the R programming language, v4, freely available for download on https://www.r-project.org/,
as well as in the Python programming language version 3.10, available
for download on https://www.python.org/downloads/. The relevant
packages used for analyses are listed in the corresponding methods
sections.

4 = G1 & G2
Bayesian inference was performed using “No U-turn sampling”91.
Highest density intervals (HDI) of the posterior estimation of group
differences (∆) were used to determine statistical certainty (***: 99%
HDI > 0 or < 0, **: 95%HDI, *:90% HDI). The BEST code was implemented following the pymc3 documentation.
Cross-validated logistic regression to associate BSI cases with ASV
composition. We ﬁrst removed ASVs with low prevalence (present in
fewer than 5% of all samples), and low abundances (maximum
observed relative abundance < 0.01) leaving 269 ASVs. We then scaled
the ASV relative abundances between 0 and 1 (min–max scaling) and
performed logistic regressions, relating ASV abundances to BSI status
(1: BSI, 0: non-BSI) using the scikit-learn v1.1 linear_model.LogisticRegressionCV module for the Python programming language with an L1
(lasso) penalty, iterating over a range of regularization strengths
([0.01, 0.1, 1, 10, 100, 1000]) using the “liblinear” solver. We retained
the inferred ASV association coefﬁcients with non-zero values for each
tested regularization strength to visualize the cross-validation path.
Bayesian logistic regression. We performed a Bayesian logistic
regression to distinguish compositional differences between infectionassociated samples and samples from patients without secondary
infections. We modeled the infection state of patient sample i, yi with a
Binomial likelihood:
yi ~ Binomialðn = 1, p = pÞ
p = inverse logisticðα + X i βÞ
α ~ Normalðμ = 0, σ = 1Þ
β ~ Normalðμ = 0, σ = 1Þ
Where prior distributions are indicated by ∼; α is the intercept of the generalized linear model, β is the coefﬁcient vector
for the log10-relative taxon abundances Xi in sample i or, in
Nature Communications | (2022)13:5926
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